***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVE This multicenter phase II Japanese Gynecologic Oncology Group study ( JGOG1067 ) was design ed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer . METHODS Patients with stage IB-IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study . The patients postoperatively received irinotecan ( CPT-11 ; 60mg/m2 intravenously on days 1 and 8) and nedaplatin ( NDP ; 80mg/m2 intravenously on day 1 ) . Chemotherapy administration commenced within 6weeks after surgery and was repeated every 28days for up to 5cycles . The primary endpoint of this study was the 2-year recurrence-free survival ( RFS ) rate . The secondary endpoints were the 5-year overall survival ( OS ) rate , 5-year RFS rate , and adverse events such as complications of chemotherapy and lower-limb edema . RESULTS Sixty-two patients were analyzed according to our protocol , among whom 55 ( 88.7 % ) completed 5cycles of scheduled treatment . The median follow-up period was 66.1months ( range , 16.8 - 96.6months ) . The 2-year and 5-year RFS rates were 87.1 % ( 95 % confidence interval [ CI ] : 75.9 - 99.3 ) and 77.2 % ( 95 % CI : 64.5 - 85.8 ) , respectively . Fourteen patients ( 22.5 % ) experienced recurrence during the follow-up period , 8 of whom died of the disease . The 5-year OS rate in this study was 86.5 % ( 95 % CI : 74.8 - 93.0 ) . Only 9.7 % of the patients experienced lymphedema in their legs . CONCLUSION Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer BACKGROUND To evaluate the efficacy of a miniaturized portable transcutaneous electrical nerve stimulation ( TENS ) unit ( ReliefB and ) as an adjunct to st and ard antiemetic therapy for controlling nausea and vomiting induced by cisplatin-based chemotherapy in gynecologic oncology patients . METHODS Forty-two patients were enrolled in a r and omized , double-blind , placebo-controlled parallel-subjects trial with a follow-up crossover trial . All patients received a st and ardized antiemetic protocol , then wore the ReliefB and continuously for 7 days . RESULTS Thirty-two patients were evaluable for the parallel-subjects component , 16 in each group . The percentage of patients with absent or minimal nausea was 59 % overall , which was similar to that for both the active ( 56 % ) and placebo ( 62 % ) groups . The incidence and severity of nausea and vomiting was similar for each group . Eighteen patients completed two consecutive cycles and were evaluable for the crossover component . The average age of the crossover patients and their dose intensity were comparable with those of the overall study population ( 56.3 versus 58.6 years and 22.7 versus 22.7 mg/m2/week , respectively ) . The percentage of cycles with absent or minimal nausea was 47 % overall , which was similar to that of the active ( 50 % ) and placebo ( 44 % ) cycles . However , the severity of nausea was significantly lower in the active cycles during days 2 to 4 . Patients averaged less than one episode of vomiting daily in each cycle . CONCLUSIONS The ReliefB and is an effective adjunct to st and ard antiemetic agents for controlling nausea induced by cisplatin-based chemotherapy in gynecologic oncology patients OBJECTIVES . The aim of this study was to compare 4 versus 6 courses of adjuvant chemotherapy after neoadjuvant chemotherapy plus radical surgery  in terms of overall survival ( OS ) , disease-free survival ( DFS ) , recurrence rate and toxicity profile . METHODS . We r and omly assigned 200 patients with IB2-IIB cervical cancer to receive 4 ( Group A ) or 6 ( Group B ) courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days . RESULTS . At 4-years follow-up , the comparison of recurrence rate ( p = 1 ; RR = 1.005 ; 95 % CI = 0.87 to 1.161 ) , OS ( p = 0.906 ) and DFS ( p = 0.825 ) did not show statistically significant differences between the two groups . Data analysis showed statistically significant differences between the two groups in term of episodes of leukopenia ( p = 0.0072 ; RR = 1.513 ; 95 % CI = 1.127 - 2.03 ) , anemia ( p = 0.048 ; RR = 1.188 ; CI = 1.012 - 1.395 ) and febrile neutropenia ( p = 0.042 ; RR = 1.119 ; 95 % CI = 1.014 - 1.235 ) , in favor of Group A. As regards non-hematological toxicities , there were no statistically significant differences in terms of gastrointestinal symptoms ( p = 0.49 ; RR = 1.046 ; CI = 0.948 - 1.153 . On the contrary , there was a statistically significant difference regarding neurological symptoms ( p=0.014 ; RR=1.208 ; CI=1.046 - 1.395 ) , that were less frequent in Group A ( 13 % ) than in Group B ( 28 % ) . CONCLUSIONS . Adjuvant treatment with 4 or 6 courses of platinum-based chemotherapy showed similar results in terms of OS and DSF , with a favorable toxicity profile in favor of the first regimen CONTEXT Chemotherapy-induced peripheral neuropathy ( CIPN ) is a major dose-limiting and persistent consequence of numerous classes of antineoplastic agents , affecting up to 30%-40 % of patients . To date , there is no effective prevention or therapy . An evolving hypothesis for reducing CIPN pain involves direct nerve stimulation to reduce the pain impulse . OBJECTIVES To evaluate the impact on CIPN associated with the MC5-A Calmare ® therapy device . METHODS The MC5-A Calmare ® therapy device is design ed to generate a patient-specific cutaneous electrostimulation to reduce the abnormal pain intensity . Sixteen patients from one center received one-hour interventions daily over 10 working days . RESULTS Of 18 patients , 16 were evaluable . The mean age of the patients was 58.6 years-four men and 14 women- and the duration of CIPN was three months to eight years . The most common drugs were taxanes , platinums , and bortezomib ( Velcade , Millenium Pharmaceuticals , Cambridge MA ) . At the end of the study ( Day 10 ) , a 20 % reduction in numeric pain scores was achieved in 15 of 16 patients . The pain score fell 59 % from 5.81±1.11 before treatment to 2.38±1.82 at the end of 10 days ( P<0.0001 by paired t-test ) . A daily treatment benefit was seen with a strong statistically significant difference between the pre- and post-daily pain scores ( P<0.001 ) . Four patients had their CIPN reduced to zero . A repeated- measures analysis using the scores from all 10 days confirmed these results . No toxicity was seen . Some responses have been durable without maintenance . CONCLUSION Patient-specific cutaneous electrostimulation with the MC5-A Calmare ® device appears to dramatically reduce pain in refractory CIPN patients with no toxicity . Further studies are underway to define the benefit , mechanisms of action , and optimal schedule Background Many patients experience nausea and vomiting during chemotherapy treatment . Evidence demonstrates that electroacupuncture is beneficial for controlling chemotherapy-induced nausea and vomiting ( CINV ) . However , the acupoint or matching acupoint with the best efficacy for controlling CINV still remains unidentified . Methods / Design This study consists of a r and omized controlled trial ( RCT ) with four parallel arms : a  control group and  three electroacupuncture groups ( one with Neiguan ( PC6 ) , one with Zhongwan ( CV12 ) , and one with both PC6 and CV12 ) . The control group received st and ard antiemetic only , while the other three groups received electroacupuncture stimulation with different acupoints besides the st and ard antiemetic . The intervention is done once daily from the first day ( day 1 ) to the fourth day ( day 4 ) during chemotherapy treatment . The primary outcome measures include frequency of nausea , vomiting and retching . The secondary outcome measures are the grade of constipation and diarrhea , electrogastrogram , assessment of quality of life , assessment of anxiety and depression , and other adverse effects during the chemotherapy . Assessment s are scheduled from one day pre-chemotherapy ( day 0 ) to the fifth day of chemotherapy ( day 5 ) . Follow-ups are done from day 6 to day 21 . Discussion The aim of this study is to evaluate the efficacy and safety of electro-acupuncture with different acupoints in the management of CINV.Trial registration The register number of r and omized controlled trial is NCT02195908 . The date of registration was 21 July 2014 PURPOSE The aim of this Phase II , non-r and omized study was to assess activity and safety of neoadjuvant chemotherapy ( NACT ) before chemoradiation ( CT/RT ) followed by radical surgery ( RS ) in locally advanced cervical cancer ( LACC ) patients . METHODS AND MATERIAL S The primary end point was rate of pathologic complete response ( pCR ) .  FIGO Stage IB2-IVA patients were administered NACT chemotherapy ( paclitaxel 80 mg/m2 , carboplatin AUC 2 ) , for 6 weeks , followed by Intensity Modulated Radiotherapy plus simultaneous boost ( total dose of 50.4 Gy to CTV1 , and 39.6 Gy to CTV2 ) . Clinical response was assessed according to RECIST criteria . Responsive patients were triaged to RS . The regimen would be considered active if > 20 pCRs were registered in 39 patients . RESULTS 45 patients were enrolled into the study ; 25 patients ( 55.5 % ) were FIGO stage IIB , 9 cases ( 20.0 % ) had stage III disease . At work up , pelvic lymph node involvement was documented in 38 ( 84.4 % ) patients ; pCR was documented in 18 out of 40 patients ( 45.0 % ) . Grade 3 - 4 hematological toxicity after NACT occurred in 4 patients ; CT/RT associated grade 3 toxicity was found in 7 patients . Early and late postoperative complications were detected in 16 , and 11 cases , respectively . Three-year PFS and OS were 66.0 % and 86.0 % , respectively . CONCLUSIONS NACT followed by CT/RT by IMRT and RS , is feasible and safe ; failure to achieve the primary endpoint has to be recognized ; however , enrollment of a higher rate of poor prognosis patients compared to historical data used to calculate sample size , could have result ed in reduced activity A prospect i ve phase 2 study was conducted to evaluate the clinical utility of acupuncture-like transcutaneous nerve stimulation ( ALTENS ) for the treatment of chemotherapy-induced peripheral neuropathy ( CIPN ) . Eligible cancer patients had a < 2 ECOG performance score , received neurotoxic chemotherapy , and developed CIPN symptoms for > two months . R and omization was used to eliminate bias in patient selection for ALTENS and was not to compare the effectiveness between the two treatments . ALTENS treatments were delivered using Codetron units . Bilateral acupuncture points included LI4 and LIV3 , plus LI11 or ST36 were stimulated . Acupuncture treatments were administered to CV6 , SP6 , ST6 , LI11 , Bafeng , Baxie and selective Jing points bilaterally . Twelve treatments were delivered twice weekly over 6 to 8 weeks . The Modified Total Neuropathy Score ( mTNS ) , Numbness Score , and Edmonton Symptom Assessment Score ( ESAS ) were assessed at baseline , treatment completion , plus at 3 and 6 months follow-up . The primary study endpoint was mTNS score at 6 months . We planned to recruit 23 patients into each group . After 30 patients were recruited , 2 were lost to follow-up at 3 months in the ALTENS group and 3 in the acupuncture group . The research team decided to recruit all remaining consecutive patients only to the ALTENS group to ensure an adequate evaluation of ALTENS , the primary object of evaluation . There were 27 patients in the ALTENS group , with an average symptom duration of 10 months after chemotherapy . Twenty four and 23 patients completed the 3 and 6 month follow-up respectively . The median mTNS scores were 7.1 , 4.0 , 3.6 and 3.1 at baseline , treatment completion , 3 and 6 months follow-up , respectively . One-way ANOVA analysis showed a significant improvement in mTNS scores ( p 
    Output:
    
Results : This systematic review will assess the effectiveness of ES on AEs caused by chemotherapy in patients with CC .
Conclusion : The findings of this study may summarize the latest evidence for the ES on AEs following chemotherapy for CC .